Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | THRB | P10828 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3736265 | 0.86 | S1PR1 (0.47) | TP53SMN1; SMN2CETPPOLBHPSE | |
| SCHEMBL3736330 | 0.86 | KDR (0.47) | MAPTTP53SMN1; SMN2CETPPOLB | |
| SCHEMBL3733136 | 0.84 | HDAC6 (0.50) | MAPTTP53SMN1; SMN2CETPPOLB | |
| SCHEMBL6048297 | 0.83 | CETP (0.44) | MAPTLMNATP53SMN1; SMN2CETP | |
| SCHEMBL3734221 | 0.83 | CETP (0.44) | MAPTLMNATP53SMN1; SMN2CETP | |
| SCHEMBL3742292 | 0.82 | S1PR1 (0.42) | CETPPOLBHPSENPC1CASP3 | |
| SCHEMBL3728482 | 0.82 | UTRN (0.48) | MAPTTHRBTP53SMN1; SMN2CETP | |
| SCHEMBL3741781 | 0.82 | P2RY14 (0.45) | MAPTTHRBLMNATP53SMN1; SMN2 | |
| SCHEMBL3733297 | 0.81 | S1PR1 (0.43) | MAPTTHRBTP53SMN1; SMN2POLB | |
| SCHEMBL3730952 | 0.81 | MAPT (0.52) | MAPTTHRBTP53SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825260-B2 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20060211656-A1 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG (CH) | 2006-09-21 | — | — | US | disclosed |
| EP-1622866-A1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096757-A1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211656-A1 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | S1PR1, S1PR3, S1PR2 | SLC2A1 2226/4885MAPT 3855/4885THRB 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.